SCHEMBL2385964

SCHEMBL2385964

CCOC(=O)[C@H](Cc1ccccc1)N(N[C@@H](Cc1ccc(C)cc1)C(=O)O)C(=O)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TACR1 P25103 1/20 0.42
PPARG P37231 1/20 0.41
MMP8 P22894 1/20 0.41
ABCB1 P08183 2/20 0.41
CTSL P07711 2/20 0.41
CTSK P43235 1/20 0.41
POLB P06746 1/20 0.40
P2RX7 Q99572 1/20 0.40
ELANE P08246 1/20 0.39
HPRT1 P00492 1/20 0.39
MME P08473 1/20 0.39
ACE P12821 1/20 0.39
CPA1 P15085 1/20 0.39
ACE2 Q9BYF1 1/20 0.39
ITGB3 P05106 2/20 0.39
ITGA2B P08514 2/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385988 0.96 MMP8 (0.44) L3MBTL1TACR1PPARGMMP8ABCB1
SCHEMBL2387334 0.94 CTSL (0.45) PPARGMMP8ABCB1CTSLCTSK
SCHEMBL2387926 0.94 PPARG (0.42) L3MBTL1TACR1PPARGMMP8ABCB1
SCHEMBL2386712 0.93 ATM (0.49) ATML3MBTL1TACR1PPARGABCB1
SCHEMBL2385924 0.92 TACR1 (0.50) TACR1PPARGMMP8ABCB1CTSL
SCHEMBL2386914 0.92 MME (0.41) PPARGMMP8ABCB1CTSLELANE
SCHEMBL2386647 0.91 KMT2A (0.47) ATMPPARGCTSLCTSKMME
SCHEMBL2385104 0.91 POLB (0.50) TACR1PPARGMMP8ABCB1CTSL
SCHEMBL2388332 0.91 PPARG (0.53) L3MBTL1PPARGMMP8MMEACE
SCHEMBL2384481 0.91 MEN1 (0.43) TACR1PPARGMMP8ABCB1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017378-B2 Method for production of optically active biphenylalanine compound or salt or ester thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-13 US disclosed
EP-1980622-B1 METHOD FOR PRODUCTION OF AN OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF SUMITOMO CHEMICAL CO (JP) 2010-08-18 EP disclosed
US-20090011475-A1 Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-08 US disclosed
EP-1980622-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF Sumitomo Chemical Company, Limited (JP) 2008-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090011475-A1 Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof DNPEP, APEH, PAH ATM 4397/4885L3MBTL1 975/4885TACR1 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.